Compounded Tirzepatide · Ranked · Updated July 2026

The 10 Best Tirzepatide Programs of 2026

We scored 10 U.S. telehealth programs offering compounded tirzepatide on a five-part rubric: price transparency, pharmacy sourcing, review score, clinical oversight, and support. MaxLife ranks first for flat all-in tirzepatide pricing from $195/mo ($150/mo on a 12-month plan), named pharmacy partners, and a clean regulatory record. Mochi leads on clinical depth; Ivim on low tirzepatide entry price. Compounded tirzepatide is not FDA-approved.

10 programs reviewed No paid placements Rubric-scored, same criteria Pricing verified Jun 2026 Clinician-reviewed
Reviewed by {{Medical Reviewer Name, Credential}} Last updated July 3, 2026
Advertising disclosure: Top 10 Tirzepatide is published by Generation Health, LLC and is supported by referral commissions. We may earn a commission when you enroll with a provider we feature here, including MaxLife, our #1-ranked pick. That is a financial interest you should weigh. Every provider is scored on the same published rubric.
Editor's Pick · #1 of 10 · Best tirzepatide value
ML MaxLife Compounded tirzepatide · all 50 states · no membership fee
9.2/10

MaxLife wins on the two most heavily weighted criteria in our rubric: it publishes flat, all-in tirzepatide pricing with no membership fee and names its pharmacy partners. Its tirzepatide starts at $195/mo and drops to $150/mo on a 12-month plan — the lowest transparent injectable-tirzepatide entry price we reviewed. Add a 4.4 Trustpilot score, all-50-state coverage, and no lawsuit or FDA warning letter on record, and it is the most transparent tirzepatide option we found.

Flat all-in tirzepatide pricing Names pharmacy partners All 50 states Money-back guarantee Clean regulatory record
Tirzepatide
$195/mo
$150/mo on 12-mo plan
Semaglutide
$175/mo
$135/mo on 12-mo plan

The full ranking

2026 Tirzepatide Program Rankings

# Provider Score Tirzepatide Semaglutide Names pharmacy Reviews
1
MLMaxLife Top PickNo membership · names pharmacy
9.2
$195/mo$150 (12-mo)
$175/mo$135 (12-mo)
✓ Yes
4.4 ★
~239
Visit →
2
MoMochi HealthVideo visits + dietitian
7.6
$199/mo+ membership
$99/mo+ $79 membership
Not named
4.4 ★
~15.6k
Review
3
TrTrimRxFlat all-in + guarantee
7.3
$349/mo$283 (12-mo)
$199/mo$174 (12-mo)
Not named
3.4 ★
verify
Review
4
EdEdenNo membership fee
7.1
$329/mo$249 first mo
$229/mo$149 first mo
Not named Review
5
ivIvim HealthIndividualized dosing
6.9
from $133+ $75 membership
from $75+ $75 membership
Not named Review
6
HHenry MedsOral & sublingual formats
6.8
oral $349+verify live
inj $297+oral fr $249
✓ Hallandale
4.5 ★‡
~12.5k
Review
7
ZZealthyInsurance coordination
6.6
$216/mo+ $135 membership
$151/mo3-mo + $135 mbr
Not named Review
8
WWillowNo membership · ~33 states
6.4
$299–549by dose
$299/moflat
Not named Review
9
FeFella HealthMen-focused program
6.2
$399/mo$249 (3-mo)
$299/mo$99 (12-mo)
Not named Review
10
EmEmergeDose-tiered · no membership
6.0
$287–419by dose
Not offeredtirz-only
✓ Empower/Hallandale + Review

Scores follow our published rubric, read through a tirzepatide lens: pricing transparency (25%), pharmacy disclosure (25%), review score & volume (20%), clinical oversight (15%), support & guarantee (15%). Program pricing and review figures were sourced June 2026 and change frequently — verify on each program's own site before deciding.
‡ Henry Meds' Trustpilot listing has been flagged for suspected incentivized reviews. Where a program does not publicly name its current compounding pharmacy, we mark it "Not named." "Verify" means the figure was not confirmable to a primary source at publication.

Compounded medication notice: Compounded tirzepatide and semaglutide are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. They are prepared by U.S.-licensed compounding pharmacies when a licensed provider determines treatment is appropriate. Compounded tirzepatide is not Mounjaro® or Zepbound®; compounded semaglutide is not Ozempic® or Wegovy®. MaxLife is not affiliated with Eli Lilly or Novo Nordisk.

Why MaxLife ranks #1

The tirzepatide transparency case, criterion by criterion

Pricing transparency (25%) — leads the field

MaxLife publishes one flat tirzepatide price with no separate membership fee and no per-dose upcharge: $195/mo, dropping to $150/mo on a 12-month plan. That is the lowest transparent injectable-tirzepatide entry price among the programs here. Several competitors bill a membership on top of the medication (Mochi $79, Ivim $75, Zealthy $135) or gate the real tirzepatide number behind an intake quiz (Henry Meds), and others price tirzepatide far higher (TrimRx $349, Fella $399, Willow's dose-tiered tirzepatide climbing to about $549).

Pharmacy disclosure (25%) — names its partners

Because compounded tirzepatide is not FDA-approved, the pharmacy is the main quality signal. MaxLife names its licensed U.S. pharmacy partners; most of the ten programs here do not publicly name their current compounding pharmacy, which removes the patient's ability to verify tirzepatide sourcing.

Reviews & record (20%) — strong rating, clean docket

MaxLife holds a 4.4 Trustpilot score. As of June 2026 it has no manufacturer lawsuit or FDA warning letter on record — a meaningful signal in a category under active regulatory scrutiny, where several ranked programs face litigation or documented safety actions.

Honest trade-offs. MaxLife's review base (~239) is far smaller than Mochi's (~15.6k) or Henry Meds' (~12.5k). Its tirzepatide is compounded, which is not FDA-approved. Ivim's tirzepatide entry price (from $133/mo before membership) can undercut MaxLife's on a low dose. Patients who want FDA-approved branded tirzepatide (Zepbound®) or insurance billing may prefer a branded program — see the note below.

Clinical evidence

What the tirzepatide trials showed

Compounded tirzepatide has not been studied in these trials. The figures below are for the branded, FDA-approved molecules and are provided as context. Individual results vary and are not guaranteed.

MoleculeTrialAvg. weight lossDuration
Tirzepatide (Zepbound®)SURMOUNT-1 · NEJM 2022~24.3%72 weeks
Semaglutide (Wegovy®)STEP 1 · NEJM 2021~15%68 weeks

Trials paired medication with diet and exercise. Sources: Jastreboff et al., NEJM 2022 (SURMOUNT-1); Wilding et al., NEJM 2021 (STEP 1).

Our method

How we rank tirzepatide programs

Every program is scored on the same five criteria, weighted by how much they affect a patient's outcome and wallet:

  • Pricing transparency (25%) — flat all-in tirzepatide pricing vs. hidden membership or dose fees.
  • Pharmacy disclosure (25%) — does the program name its compounding pharmacy and offer testing documentation?
  • Review score & volume (20%) — verified ratings across Trustpilot, BBB, and app stores.
  • Clinical oversight (15%) — video vs. async visits, dietitian access, monitoring.
  • Support & guarantee (15%) — responsiveness, refund terms, results guarantee.
Advertising disclosure: Top 10 Tirzepatide is published by Generation Health, LLC and earns referral commissions from providers we feature, including MaxLife, our #1-ranked pick. We score every provider on the identical rubric and disclose real trade-offs, but you should weigh our financial interest. We do not present this site as impartial.
Prefer FDA-approved branded tirzepatide? This ranking covers compounded tirzepatide programs. Providers such as Ro and Hims & Hers now focus on branded, FDA-approved tirzepatide (Zepbound®, Mounjaro®) with insurance navigation, following 2025–2026 industry settlements — a different path, at typically higher cash prices. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company; MaxLife and Top 10 Tirzepatide are not affiliated with Eli Lilly. We compare those routes in our program guides.
Medically reviewed by {{Medical Reviewer Name, Credential}} Board-certified · last clinically reviewed July 3, 2026
Researched & written by The Top 10 Tirzepatide editorial team Pricing verified against provider sites, June 2026

Frequently asked questions

Which tirzepatide program is best in 2026?

It depends on your priorities. For transparent flat tirzepatide pricing, named pharmacy sourcing, and a clean regulatory record, MaxLife ranks first among the 10 programs here, with tirzepatide from $195/mo ($150/mo on a 12-month plan). Mochi stands out for included video visits and a registered dietitian; Ivim for its low tirzepatide entry price; Henry Meds for oral and sublingual tirzepatide formats.

Is compounded tirzepatide FDA-approved?

No. Compounded tirzepatide is not FDA-approved and has not been reviewed by the FDA for safety, effectiveness, or quality. It is prepared by U.S.-licensed compounding pharmacies when a licensed provider determines treatment is appropriate. Compounded tirzepatide is not Mounjaro® or Zepbound®.

Why does pharmacy transparency matter for compounded tirzepatide?

Because compounded tirzepatide is not FDA-approved, the compounding pharmacy is the primary quality signal. Programs that name their pharmacy partner and can supply a certificate of analysis (potency, sterility) give patients a way to verify what they're injecting. Most of the ten programs here do not publicly name their current pharmacy.

How much does compounded tirzepatide cost per month?

Among the programs here, compounded tirzepatide runs from roughly $133 to $549 per month, though several add a separate membership fee (Mochi, Ivim, Zealthy), gate exact pricing behind an intake form (Henry Meds), or tier it by dose (Willow, Emerge). MaxLife starts at $195/mo and drops to $150/mo on a 12-month plan. Figures were sourced in mid-2026 and change frequently; confirm current pricing and exactly what's included on each program's own site.

What's the difference between a 503A and a 503B pharmacy?

A 503A pharmacy compounds patient-specific prescriptions under state board of pharmacy oversight. A 503B outsourcing facility registers with the FDA and follows federal cGMP standards, allowing larger-batch production under more oversight. Neither status makes a compounded drug FDA-approved.

Is this an independent review site?

Top 10 Tirzepatide is published by Generation Health, LLC, which is not owned by MaxLife. It is affiliate-supported: we earn a referral commission when you enroll with providers we feature, including MaxLife, which we rank #1. Because of that financial interest, we do not present our rankings as impartial — we score every provider on the same published rubric and disclose trade-offs. Verify current details on each provider's own site.